Description

Spartan 3 (Mod GRF 1-29/CJC-1295 No Dac + GHRP-6) Peptide Vials

Spartan 3 (Mod GRF 1-29 + GHRP-6) contains 5mg of Mod GRF 1-29/CJC-1295 No Dac and 5mg of GHRP-6, totaling 10mg.

GHRP-6
CAS Number	87616-84-0
Molar Mass	873.032 g·mol−1
Chemical Formula	C46H56N12O6
IUPAC Name	L-histidyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-Lysinamide

Mod grf 1-29/CJC-1295 No Dac
CAS Number	86168-78-7
Molar Mass	3357.93 g·mol−1
Chemical Formula	C149H246N44O42S
IUPAC Name	L-Tyrosyl-L-alanyl-L-α-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide

Introduction

Spartan 3, a research peptide combination of Mod GRF 1-29 (CJC-1295 No Dac) and GHRP-6, holds promise as a valuable tool for scientific inquiry. Strictly designated for research purposes, this peptide blend is of interest to researchers exploring its potential applications within controlled laboratory settings.

Key Characteristics

Spartan 3 is characterized by its unique composition, combining Mod GRF 1-29 (CJC-1295 No Dac) and GHRP-6. Each component contributes distinct properties, making this combination a subject of scientific interest for researchers studying growth hormone regulation and related physiological processes.

Research Applications

The primary application of Spartan 3 in research lies in its potential to modulate growth hormone levels and influence various aspects of metabolism. Researchers utilize this peptide blend to investigate its impact on growth hormone deficiency, obesity, and the potential synergistic effects arising from the combination.

Research Benefits

Synergistic Effects

Spartan 3 is investigated for potential synergistic effects resulting from the combination of Mod GRF 1-29 (CJC-1295 No Dac) and GHRP-6. Researchers explore how these peptides, when combined, may exert complementary actions to enhance the overall regulatory effects on growth hormone secretion.

CJC 1295 No DAC and Treatment of Growth Hormone Deficiency

Scientific inquiries focus on the specific benefits of CJC-1295 No Dac in addressing growth hormone deficiency. Researchers aim to elucidate the peptide’s role in regulating growth hormone levels and its potential therapeutic applications in cases of deficiency.

GHRP-6 and Obesity

Studies into the role of GHRP-6 in addressing obesity provide a notable avenue for research. Investigators explore the potential of GHRP-6 to influence metabolic processes, specifically its impact on appetite regulation and fat metabolism.

Summary

In summary, Spartan 3 (Mod GRF 1-29/CJC-1295 No Dac + GHRP-6) emerges as a multifaceted research tool, offering researchers the opportunity to explore synergistic effects and individual benefits of its components. This peptide combination holds the potential to contribute to the understanding of growth hormone regulation and related therapeutic avenues.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Maletínská L, Matyšková R, Maixnerová J, Sýkora D, Pýchová M, Spolcová A, Blechová M, Drápalová J, Lacinová Z, Haluzík M, Zelezná B. The Peptidic GHS-R antagonist [D-Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity. Mol Cell Endocrinol. 2011 Aug 22;343(1-2):55-62. doi: 10.1016/j.mce.2011.06.006. Epub 2011 Jun 17. Erratum in: Mol Cell Endocrinol. 2012 Jan 2;348(1):344. PMID: 21704671. [Read More].
2. Timms M, Ganio K, Forbes G, Bailey S, Steel R. An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. 2019 Jun;11(6):804-812. doi: 10.1002/dta.2554. Epub 2018 Dec 25. PMID: 30489688. [Read More].